Stifel has recently initiated Cullinan Therapeutics Inc (CGEM) stock to Buy rating, as announced on May 1, 2024, according to Finviz. Earlier, on April 15, 2024, William Blair had initiated the stock ...

Nicholas Cullinan, the new director of the British Museum, has announced a groundbreaking $1.3 billion transformation plan, ...

After buying a Rolls-Royce Cullinan for his five-year-old daughter, this man made an equally astonishing purchase at an ...

In an effort to control the development of a Downtown Peoria block, CIty Hall wants to buy two buildings and a parking deck ...

The city of Peoria is putting together an effort to buy a trio of prominent buildings in Downtown Peoria for potential ...

BTIG analyst Julian Harrison maintained a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target of ...

The Human Research Ethics Committee (HREC) in Australia has granted clearance for Cullinan Therapeutics to commence an ...

Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic ...

Sept. 17, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today received Human Research ...

The newly-evolved Rolls-Royce Cullinan Series II appeals to the discerning tastes of ultra-luxury SUV enthusiasts through ...

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned a consensus rating of “Buy” from the six ratings firms that are currently covering the stock ...

Rolls-Royce has unveiled the Cullinan Series II, marking a bold evolution of its renowned super-luxury SUV. This latest ...